Page 62 - Read Online

Page 8 of 11 Calderon Novoa et al. Hepatoma Res 2023;9:33 https://dx.doi.org/10.20517/2394-5079.2023.36

[77]
radiological features in a cohort of 127 patient . The field of AI and its applicability in oncology is a
growing one and will likely affect follow-up regimes, shifting the paradigm towards patient-tailored
follow-up. If we consider LT an extremely radical resection with R0 margins, many of the risk factors and
outcomes from LR are likely to be shared, and nomograms and calculators such as the “metro ticket” may
help the team in deciding follow-up timing and imaging, which should likely be performed routinely every
three months for the first year with high-quality imaging such as CT or MRI scans, and then reassessed
depending on each patient’s individual risk factors.

CONCLUSIONS
There is not enough evidence to consider LT the gold standard for iCCA. However, there seem to be
promising results when patients are correctly selected, and prospective trials combining systemic NAC and
locoregional treatments with LT have shown very interesting long-term results.

DECLARATIONS
Authors’ contributions
Made substantial contributions to the conception and design of the study, literature search writing, and
proofreading: Calderon Novoa F
Conception and design of the study, proofreading: de Santibañes M
Design of study, literature search, and writing: Ardiles V
Conception and design of the study, proofreading: Matera J
Literature search, writing, and proofreading: Pekolj J

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:101-4. DOI
PubMed PMC
2. Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int
2019;39 Suppl 1:7-18. DOI
3. Liao X, Zhang D. The 8th edition american joint committee on cancer staging for hepato-pancreato-biliary cancer: a review and
update. Arch Pathol Lab Med 2021;145:543-153. DOI
4. Nakanuma Y, Kakuda Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol
2015;29:277-93. DOI PubMed